London, United Kingdom
London, United Kingdom

Silence Therapeutics is a biotechnology company that develops gene therapeutic technology based on RNA interference . They are involved in developmental research of targeted RNAi therapeutics for the treatment of serious diseases. Formed in 1994 as a publicly traded drug research and development company, Silence Therapeutics has offices in London and Berlin, with its corporate headquarters based at 1 Lyric Square, London. Wikipedia.

SEARCH FILTERS
Time filter
Source Type

Patent
Silence Therapeutics | Date: 2016-10-20

The present invention is related to uses of a composition comprising a pharmaceutically active component and a compound according to formula (I),


Patent
Silence Therapeutics | Date: 2017-04-26

The present invention discloses modified guide RNAs which can be used with the CRISPR CAS 9 system for modifying gene expression, particularly in mammalian cells for medical or research uses.


Patent
Silence Therapeutics | Date: 2017-10-11

The present invention relates to a compound comprising a modified saccharide moiety conjugated to a nucleic acid. The compound is useful in medicine for RNA interference therapy or for research and diagnostic purposes. In particular, the compound is useful in treating liver disease.


Patent
Silence Therapeutics | Date: 2017-09-27

The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double- stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.


Patent
Silence Therapeutics | Date: 2017-09-27

The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double- stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.


Patent
Silence Therapeutics | Date: 2017-09-27

The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double- stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.


Patent
Silence Therapeutics | Date: 2015-12-22

The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.


Patent
Silence Therapeutics | Date: 2016-03-09

The present invention is related to a lipid composition comprisingat least a first lipid component,at least a first helper lipid, anda shielding compound which is removable from the lipid composition under in vivo conditions.


Patent
Silence Therapeutics | Date: 2016-03-09

The present invention is related to a lipid composition contained in and/or containing a carrier comprising at least a first lipid component, at least a first helper lipid, and a shielding compound which is optionally removable from the lipid composition under in vivo conditions, whereby the lipid composition containing carrier has an osmolality of about 50 to 600 mosmole/kg, preferably about 250 - 350 mosmole/kg, and more preferably about 280 to 320 mosmole/kg, and/or whereby liposomes formed by the first lipid component and/or one or both of the helper lipid and the shielding compound in the carrier have a particle size of about 20 to 200 nm, preferably about 30 to 100 nm, and more preferably about 40 to 80 nm.


Patent
Silence Therapeutics | Date: 2016-07-06

The present invention is related to use of protein kinase N beta or a fragment or derivative thereof as a downstream target of the PI 3-kinase pathway, preferably as a downstream drug target of the PI 3-kinase pathway.

Loading Silence Therapeutics collaborators
Loading Silence Therapeutics collaborators